

EFFECTIVE DATE: 01|01|2018

POLICY LAST UPDATED: 01|16|2018

OVERVIEW

Parsabiv is a calcium-sensing receptor agonist indicated for Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

MEDICAL CRITERIA

Initial and Renewal Evaluation

Parsabiv (etelcalcetide) will be approved when ALL of the following are met:

1. The patient has a diagnosis of secondary hyperparathyroidism with chronic kidney disease
AND
2. The patient is on hemodialysis
AND
3. The patient's corrected serum calcium is at or above the lower limit of the normal range
AND
4. The patient has a pre-treatment or current intact PTH (iPTH) level of greater than or equal to 300 pg/mL
AND
5. The patient does not have any one of the following limitations to the use of Parsabiv:
 - a. Parathyroid carcinoma **OR**
 - b. Primary hyperparathyroidism**AND**
6. ONE of the following:
 - a) The patient's medication history includes previous use of a prerequisite agent (Sensipar (cinacalcet) and had an inadequate response to treatment (inadequate reduction in iPTH) **OR**
 - b) The patient has a documented intolerance, FDA labeled contraindication, or developed hypocalcemia from treatment

Length of Approval: 12 months.

PRIOR AUTHORIZATION

Prior authorization is required for BlueCHiP for Medicare and recommended for Commercial Products

POLICY STATEMENT

BlueCHiP for Medicare and Commercial Products

Etelcalcetide (Parsabiv) is medically necessary when all of the criteria have been met.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable physician administered benefits/coverage.

BACKGROUND

Secondary hyperparathyroidism (HPT) is a frequent complication in patients with chronic kidney disease (CKD). It is characterized by elevated phosphorus and vitamin D deficiency. The implications of untreated secondary HPT include renal bone disease, weakness, fractures, bone and muscle pain, as well as avascular necrosis.

Management of secondary HPT in patients with dialysis involves dietary phosphate restriction and use of a combination of phosphate binders (e.g. calcium acetate, Renagel, Renvela, Fosrenol), vitamin D analogs (e.g. calcitriol, paricalcitol, doxercalciferol), and/or calcimimetics (e.g. Sensipar, Parsabiv). The goal of therapy is to maintain serum level of phosphorus between 3.5 and 5.5 mg/dL.

CODING

BlueCHiP for Medicare and Commercial Products

The following code is medically necessary when the criteria are met:

J0606 Injection, etelcalcetide, 0.1 mg (New code effective 1/1/2018)

RELATED POLICIES

None

PUBLISHED

Provider Update, March 2018

REFERENCES:

1. Parsabiv prescribing information. Amgen. April 2017

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

